Search
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalIt is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.
Asimadoline
go.drugbank.com/drugs/DB05104InvestigationalIt has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.
Flunixin
go.drugbank.com/drugs/DB11518ExperimentalVet approvedIt exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form.
Amredobresib
go.drugbank.com/drugs/DB21566InvestigationalThe usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10596ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10597ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10776ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10777ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10778ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10802ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it